GlassScriptPhysician profile
Sungchun Lee
NPI 1033112818
$4,761.26
in general payments reported to CMS, 2019-2025
32 companies · $1,109 in 2025
The $1,109 reported for 2025 was more than what 80% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $612 · 2020: $351 · 2021: $397 · 2022: $663 · 2023: $850 · 2024: $780 · 2025: $1,109.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,509 · Education: $229.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,509.38 |
| Education | $229.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $674.01 | 2019-2025 | Farxiga |
| Opko Pharmaceuticals, LLC | $529.66 | 2019-2025 | Rayaldee |
| Otsuka America Pharmaceutical, INC. | $443.57 | 2019-2025 | Jynarque, Voyxact |
| Vifor Pharma, INC. | $283.16 | 2019-2022 | |
| Novo Nordisk INC | $278.11 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $273.33 | 2024-2025 | Krystexxa, Tavneos |
| Arbor Pharmaceuticals, INC. | $238.39 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $233.41 | 2023-2025 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $229.61 | 2022-2023 | Lifevest |
| Horizon Therapeutics Plc | $215.19 | 2021-2023 | Krystexxa |
| Abiomed | $140.38 | 2022 | |
| Ardelyx, INC. | $139.13 | 2023-2025 | Ibsrela |
| Calliditas Therapeutics US INC. | $133.86 | 2023-2025 | Tarpeyo |
| Akebia Therapeutics INC | $133.28 | 2019-2025 | Vafseo |
| Axonics, INC. | $126.03 | 2023 | Axonics, Bulkamid |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $101.25 | 2020-2025 | Acthar |
| Kerecis Limited | $96.70 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Lilly USA, LLC | $85.23 | 2024-2025 | Jardiance |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $68.68 | 2019-2020 | |
| Travere Therapeutics, INC. | $62.00 | 2023-2024 | |
| Lundbeck LLC | $56.16 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $39.52 | 2022-2025 | |
| Glaxosmithkline, LLC. | $27.85 | 2021 | |
| Aurinia Pharma U.S., INC. | $24.09 | 2021 | |
| Novartis Pharmaceuticals Corporation | $21.08 | 2025 | |
| Genentech USA, INC. | $20.03 | 2019 | |
| Boston Scientific Corporation | $19.79 | 2023 | |
| Daiichi Sankyo INC. | $18.87 | 2023 | Injectafer |
| Fresenius USA Marketing, INC. | $17.68 | 2019 | |
| Azurity Pharmaceuticals, INC. | $16.82 | 2023 | Edarbi |
| Alexion Pharmaceuticals, INC. | $14.39 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sungchun Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.